A rapid scoping review of harm reduction strategies for ecstasy (MDMA) users in recreational settings

Edwards and colleagues frame MDMA (ecstasy) as a commonly used recreational stimulant whose sought effects include euphoria, increased energy, musical appreciation and emotional closeness. The introduction emphasises that illicitly produced MDMA varies in form and purity and is often used in hot, prolonged-dancing settings such as nightclubs and festivals, which raises the risk of adverse drug reactions (ADRs) including hyperthermia and hyponatraemia. The authors note a wide spectrum of other reported harms from mild (e.g. bruxism, nausea) to severe outcomes (e.g. hepatotoxicity, acute renal failure, seizure, coma, death), and describe increasing MDMA-related deaths in England and Wales over the past decade. They position harm reduction—ranging from simple behaviours (drinking water, taking breaks) to service-level interventions (free water, chill-out spaces, drug checking/pill testing)—as potentially mitigative but under-reviewed in the ecstasy-specific context. This rapid scoping review aimed to map the range and prevalence of harm reduction strategies used by people who consume ecstasy in recreational settings, and to identify where users obtain harm-reduction information. The study also sought to catalogue MDMA-specific harm-reduction content on user-oriented drug information websites, motivated by the practical need to target effective education and to assess the credibility of commonly cited online sources.

The researchers conducted a rapid scoping review using adapted JBI methodology and reported according to the PRISMA-ScR extension. To expedite the review they streamlined some processes (for example, searching a limited set of databases and not performing a formal quality appraisal), while following established scoping review procedures. Their protocol was registered on the Open Science Framework (details not provided in the extracted text). Eligibility was defined using the PCC framework (Participants, Concept, Context), although the extracted text does not reproduce the full inclusion/exclusion table. Searches covered four bibliographic databases (CINAHL on EBSCO; EMBASE, Medline, APA PsycINFO, and CENTRAL on Ovid) from inception to August 2022, using search terms for methylenedioxy-N-methylamphetamine, MDMA or ecstasy combined with harm-reduction-related terms. Forward and backward citation tracking was performed using Citation Chaser™. Records were managed in EndNote X20™ and screened in Rayyan™. In addition to peer-reviewed literature, the team identified user-oriented websites by consulting a project stakeholder group and by conducting Google searches with terms such as "harm reduction and ecstasy" and "safe and MDMA"; one reviewer screened the first page of each Google result for relevant UK websites. Two reviewers screened titles and abstracts with disagreements resolved by discussion; full-text screening was performed by one reviewer with checking by a second. Data extraction for studies captured demographics, study design and findings relevant to the review objectives; extraction was done by one reviewer and 50% checked by another, supported by NVIVO 12 Plus™. For websites, the extracted items included webpage title, country, date, URL and specific MDMA harm-reduction content; extraction was similarly checked. No formal quality appraisal was conducted. Results were synthesised into tables and a narrative summary following Arksey and O'Malley’s approach as updated in later scoping review guidance.

The search yielded 877 records; after screening 37 full texts were assessed and 20 reports representing 19 studies were included. After duplicate removal, 30 websites were screened and 15 user-oriented sites met the inclusion criteria. Among the 19 studies there was one randomised controlled trial (RCT), nine quantitative descriptive studies and nine qualitative studies reported across the included documents. Geographically, studies were conducted in Australia (n = 6), the USA (n = 5 across six reports), the UK (n = 2), the Netherlands and several multi-country studies often including USA, UK, Canada and other jurisdictions. Participants were predominantly ecstasy users (14 studies, 15 reports), with other samples including ecstasy sellers, key informants (e.g. drug checkers), and festival attendees. Most studies focused on young adults: nine studies (across 10 reports) reported mean ages under 30 (range 21–28), with participant ages across studies spanning from 16 up to 51–60 years. A broad array of harm-reduction strategies were reported and were grouped by the reviewers into drug-related, behavioural and peer-related approaches. Drug-related strategies included drug checking/pill testing (reported in ten studies), visual inspection of tablets, limiting frequency and dose (for example taking half a tablet or dissolving under the tongue), sourcing from trusted suppliers, and only using a new batch after observing others’ reactions. Quantitative analyses linked psychological determinants to drug-checking intentions: attitudes, subjective norms and perceived behavioural control showed significant positive associations with intention to use drug checking (p < 0.001 for attitudes and subjective norms; perceived control p < 0.05), and higher baseline intention predicted subsequent use of checking services (p = 0.018). Risk-reduction after pill-testing varied: users were more likely to follow safer behaviours when clear harmful adulterants were identified, but some reported taking tablets even when a high MDMA dose was found. Sensation-seeking scores were associated with lower likelihood of harm-reducing behaviour when tests indicated high MDMA (p < 0.01). Behavioural strategies commonly cited were taking rest breaks from dancing or using designated cool-down spaces to reduce hyperthermia risk, and drinking fluids to prevent dehydration. However, practical barriers (limited free water, queues at outdoor events) were noted. Only one included study reported participants referring to limiting water intake to avoid hyponatraemia. Mixing alcohol and ecstasy was variably avoided: five studies reported participants chose not to mix the two to reduce dehydration or comedown effects, whereas other participants mixed them, sometimes from lack of awareness. Preloading and post-loading (use of pharmaceuticals, supplements or foods before or after ecstasy to mitigate comedown or perceived neurotoxicity) were reported across ten studies with diverse products used; evidence supporting these practices was generally weak. Associations with pre/post-loading behaviour were inconsistent: one analysis found younger age (p = 0.011) and >50 lifetime uses (p = 0.007) associated with preloading, while post-loading associated with >50 uses (p = 0.001) and monthly+ frequency (p = 0.036); another study reported less frequent users were more likely to engage in pre/post-loading (p = 0.012). Concern about harm was associated with taking vitamin tablets as a precaution (p = 0.026). Peer strategies were frequently reported: not using alone and looking out for friends were common themes across multiple studies and webpages. Gender differences emerged in some behaviours: females were more likely to limit consumption than males (p = 0.003), while males were more likely to take rest breaks (χ2 = 5.70, p = 0.017). Regarding information sources, friends were the most popular, with friends and the internet also commonly cited; females were significantly more likely than males to use friends as an information source (p = 0.005). One RCT compared a harm-reduction leaflet or info-card against neutral material and found no significant change in attitudes or intention to use ecstasy (p > 0.05). The review examined 14 user-oriented webpages with MDMA-specific content (the extracted text refers to both 14 and 15 webpages in different places). All webpages addressed dehydration; 13/14 discussed hyperthermia and 13/14 mentioned alcohol interactions; 13/14 advised initiating use with a low test dose; 12/14 covered when to seek help; 11/14 advised waiting between uses; and fewer pages covered interactions with prescribed medications (7/14), not using alone (7/14), dosing recommendations (6/14) or drug checking (6/14). Only two webpages provided bibliographic citations to support their content; several linked to other websites. The reviewers noted that no single webpage provided a complete ‘‘one-stop’’ source of all relevant information. Drug checking uptake and utility were mixed: participants across 10 studies (reported as 53% in the text) used some form of testing. The range of testing techniques runs from reagent kits (qualitative, accessible but limited in detecting mixtures or quantifying MDMA) to laboratory analyses provided by onsite or fixed services. Prior systematic reviews and some festival surveys cited by the authors suggest drug checking can influence consumption downward when results differ from expectations, but findings in the current review were inconsistent, with some users intending to consume even when tests indicated unusually high MDMA content. On interactions and pharmacological risks, webpages commonly warned against mixing MDMA with alcohol and other drugs; 93% of webpages mentioned alcohol risks. Empirical studies showed variable avoidance of polydrug use. The reviewers highlighted potential harms from pre/post-loading with pharmacologically active agents, including sedatives and antidepressants, noting the risk of serotonin syndrome when combining MDMA with SSRIs and other serotonergic agents. On hydration, all webpages advised about dehydration risk and 11/14 discussed limiting fluid to avoid hyponatraemia; the included studies rarely recorded users limiting fluid intake. The authors reported that evidence supporting many harm-reduction practices varied substantially and was limited for several commonly used strategies, notably preloading/post-loading and certain supplements such as 5-HTP. Establishing an evidence base is challenging because preventing an avoided ADR is difficult to observe and verify. Finally, the review documents practical limitations of the rapid scoping approach and heterogeneity across included studies in how "harm reduction" was defined and measured.

Edwards and colleagues interpret their findings as showing that people who use ecstasy employ a wide and varied set of harm-reduction behaviours in recreational contexts, but that adoption is influenced by users’ goals (e.g. avoiding comedown versus maximising the high) and prior experience. The discussion emphasises that some behavioural strategies—taking rest breaks to avoid overheating, maintaining adequate but not excessive hydration, avoiding certain polydrug combinations (including alcohol), moderating dose/frequency, and not using alone—have some empirical support and are plausibly protective. By contrast, several commonly reported practices, particularly preloading and post-loading with pharmaceuticals or supplements, lack a solid evidence base and may in some cases increase risk. The authors situate their results within prior literature by noting that, while drug checking and peer education have been previously discussed, no prior review had comprehensively mapped ecstasy-specific harm reduction across peer-reviewed studies and user-facing websites. They comment that drug checking services can influence intentions and behaviour when results are unexpected, but findings are mixed in relation to how users respond to information about high potency or adulterants. The RCT identified did not show that written leaflets meaningfully shifted attitudes or intentions, suggesting that conventional information dissemination may have limited effectiveness for changing use. Key limitations acknowledged by the study team include constraints inherent to the rapid scoping approach (streamlined screening and extraction, no formal quality appraisal), possible omission of relevant studies, heterogeneity in how harm reduction was defined across included studies, and the limited generalisability given some samples skewed younger while others included older adults. The authors also note that many quantitative studies used predefined lists of strategies, potentially constraining responses, and that qualitative studies often asked about specific strategies rather than eliciting unprompted practices. Implications discussed by the authors include the need for more efficient and credible ways to communicate harm-reduction information to ecstasy users, greater involvement of service users in designing educational materials, further research into how drug-checking results influence behaviour, and more rigorous evaluation of commonly used practices (for example, the safety and efficacy of preloading/post-loading regimens). They caution that some perceived harm-reduction tactics may paradoxically increase harm and therefore warrant clearer public health messaging.

The review identified a wide variety of harm-reduction behaviours among people who use MDMA/ecstasy in recreational settings. While complete elimination of drug-related risks requires abstinence, several strategies were identified for which there is some evidence of risk reduction, including taking breaks to avoid hyperthermia, appropriate hydration, avoiding certain polydrug combinations, moderating consumption, and not using alone. Conversely, many ADR-avoidance strategies—especially preloading and post-loading with pharmaceuticals or supplements—are poorly supported by evidence and may in some cases exacerbate harm. The authors recommend improved communication strategies, participatory development of educational materials, and further research to build the evidence base for effective harm-reduction practices.